Keywords: Medivation, Dimebon, Pfizer, Alzheimer's disease

Medivation persists with Dimebon research in Alzheimer’s, despite earlier failures

Article | 08 December 2010

Print This

US biotech firm Medivation (Nasdaq: MDVN) says that patient enrollment was completed at end November in the CONCERT study, a 12 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in